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Clostridium difﬁcile binary toxin (CDT) is an ADP-ribosyltransferase which is linked to enhanced patho-
genesis of C. difﬁcile strains. CDT has dual function: domain a (CDTa) catalyses the ADP-ribosylation of
actin (enzymatic component), whereas domain b (CDTb) transports CDTa into the cytosol (transport
component). Understanding the molecular mechanism of CDT is necessary to assess its role in C. difﬁcile
infection. Identifying amino acids that are essential to CDTa function may aid drug inhibitor design to
control the severity of C. difﬁcile infections. Here we report mutations of key catalytic residues within
CDTa and their effect on CDT cytotoxicity. Rather than an all-or-nothing response, activity of CDTa mu-
tants vary with the type of amino acid substitution; S345A retains cytotoxicity whereas S345Y was
sufﬁcient to render CDT non-cytotoxic. Thus CDTa cytotoxicity levels are directly linked to ADP-ribo-
syltransferase activity.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clostridium difﬁcile is a gram positive, anaerobic bacterium that
is the leading cause of antibiotic-associated pseudomembranous
colitis worldwide. It produces two large potent exotoxins TcdA and
TcdB that are the causative agents of infection and some strains of
C. difﬁcile produce an ADP-ribosyltransferase binary toxin (CDT),
which is made up of two individually produced components, CDTa
and CDTb [1]. CDTa is the enzymatically active component
(48 kDa), whereas CDTb is the transport component (74 kDa)
(Fig. 1A), assisting CDTa’s entry into target cells [2–4]. It has been
shown that CDT is toxic to African green monkey kidney epithelial
cells (Vero cells) [5] but its precise role in pathogenesis is unclear
[6]. Using time-lapse and immunoﬂuorescence microscopy,
Schwan et al., have shown that CDT forms dynamic microtubule
protrusions on the surface of human colon carcinoma cells (Caco-an open access article under the C
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ill Laboratory, The Ridgeway,2) concomitantly with ADP-ribosylation of actin and depolymer-
isation of microﬁlaments [7]. It is thought that the binary toxin
increases adherence of bacteria to the intestinal epithelial cells
through these cell surface extensions. Schwan et al. also reported
that the protrusions form a dense meshwork in which the bacteria
were caught, contributing to the colonisation of C. difﬁcile. Similar
results were also demonstrated for the homologues C. botulinum
toxin C2 (C2) and C. perfringens Iota toxin (Ia) [2,7,8]. In addition to
protrusion formation, cellular microtubule structures were also
altered to increase bundling of microtubules.
The N-terminus of CDTa is responsible for interaction with
CDTb, whereas the C-terminus harbours the enzymatic activity
[6,9]. Structural evidence from the complex of actin with the en-
zymatic component of Ia shows that Arg-177 of actin is the ribo-
sylation site [10]. Based on homology and biochemical evidence,
we can predict that CDTa would also irreversibly ADP-ribosylate
monomeric G-actin at the Arg-177 residue. This ADP-ribosylation
blocks polymerisation of G-actin to F-actin and subsequently dis-
rupts the F-actin:G-actin equilibrium [11,12].
Previously we have reported the crystal structure of CDTa at
three different pH values, 4.0, 8.5 and 9.0 and in complex with
NADPH and NAD at pH 9.0 [13]. Both the structure of CDTa com-
bined with the mechanism of ADP-ribosylation of Ia (which shares
84% sequence identity with CDTa), have been used to propose a
detailed mechanism of ADP-ribosylation [11–13]. It was postulated
that CDTa transfers the ADP ribose group of NAD/NADPH to
monomeric G-actin at Arg-177, blocking polymerisation of actinC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) Schematic representation of the domain organisation of CDTa and CDTb of the C. difﬁcile binary toxin. The N-terminal signal peptide is displayed in grey for both
components. CDTa N-terminal domain (CTDb binding, purple) and the C-terminal domain (ADP-ribosyltransferase activity, cyan) are shown. The CDTb component has an activation
domain (yellow) that must be cleaved to give the activated domain (red). (B) Left: Key features in the CDTa active site. The N-terminal domain (residues 1-125), the C-terminal
domain (residues 224-240), and the loop region connecting both domains (residues 216-223) are displayed in purple, cyan, and yellow respectively. Actin is shown in grey. Also
shown are PN-loop (green), ARRT-loop (brown). Right: Close-up of catalytic residues. Residues of the ARRT-loop (E385, E387), Arg-motif (blue, R302, R303), NAD (orange), STS-motif
(pink, S345, S347) are shown. Images were created using PyMOL (Version 1.5.0.4 Schrödinger, LLC) using previously described CDTa structure [13].
A.H. Davies et al. / Biochemistry and Biophysics Reports 8 (2016) 55–6156and therefore leading to the collapse of the cell cytoskeleton [3].
The CDTa N-terminal domain (residues 1-215; numbering re-
fers to mature toxin without signal peptide) is proposed to interact
with CDTb whereas the C-terminal domain (residues 224-420) is
thought to interact with actin (Fig. 1B). These domains are linked
by a short loop (seven residues) [13]. Both NAD and NADPH bind to
the catalytic cleft of CDTa via the interacting residues Arg-302,
Arg-303, Gln-307, Asn-342 and Ser-345 (Fig. 1B) [13].
Fig. 1B also displays key catalytic residues in addition to a
number of other important features of the ADP-ribosylating family
of toxins, including the PN-loop and Arg-motif. The EXE-motif
which is thought to be the key motif involved in the ADP-ribosy-
lation mechanism is located on the highly ﬂexible ADP-ribosyl
turn-turn (ARTT)-loop which is important for substrate binding. In
CDTa, the EXE-motif is composed of residues Glu-385 and Glu-387,
which are thought to be involved in stabilising the substrate–en-
zyme complex as conﬁrmed with the corresponding residues Glu-
378 and Glu-380 in Ia [10]. The unusual arrangement in this
structure is that these residues are not in direct contact with NAD
or NADPH, which might suggest that the EXE-motif in CDTa is not
necessary for ligand binding and stabilisation of this complex.
However, this could be due to the location of both Glu-385 and
Glu-387 on the ﬂexible ARTT-loop [3]. The ﬁnal feature shown in
Fig. 1B is the STS-motif, which includes the residues Ser-345 and
Ser-347. The Ser-345 residue forms a strong hydrogen bond with
Glu-387, and also directly with NAD and NADPH, therefore sug-
gesting a role for the STS-motif in ligand binding and catalysis
[3,13].
An SN1 mechanism has been proposed for ADP-ribosylation of
monomeric G-actin. The mechanism was based on the mutagen-
esis studies of Ia and the crystallographic structure of actin in
complex with Ia [10]. The SN1 reaction proceeds via two con-
secutive intermediates: an oxocarbenium ion intermediate and acationic intermediate [3]. This mechanism is thought to be con-
sistent amongst the ADPRT family of toxins [14]. As Ia is the closest
homologue to CDT, a similar SN1 reaction has been proposed with
the EXE-motif playing a key role [13].
Here we report a detailed mutagenesis and biochemical study
on CDTa active site residues to determine their role in CDTa ac-
tivity and thereby testing the hypothesis of the SN1 mechanism.
This study also provides experimental evidence on the importance
of the EXE-motif in the catalytic activity of CDTa.2. Materials and methods
2.1. Cloning and expression
CDTa mutants were generated by site-directed mutagenesis
using pMAL p2X-CDTa plasmid as template. Oligonucleotides
(primers) for mutagenesis of active site residues are summarised
in Table 1. Plasmids containing cdtA inserts were transformed into
E.coli Top 10 cells and mutations conﬁrmed by DNA sequencing.
CDTa mutants were expressed in E. coli BL21 (DE3)-CodonPlus
cells. It was noted that the expression yield of both recombinant
wild-type CDTa (rCDTa) and the mutants was low. To improve
protein expression yield, pGEX-6p1 was used as expression vector:
cdtA DNA inserts were released from pMAL-p2x plasmids by re-
striction digest (BamH1 and Sal1) and ligated into the pGEX-6p1
vector. cdtA DNA inserts were checked by sequencing.
2.2. Expression of CDTa constructs
CDTa constructs were grown in LB medium containing the
appropriate antibiotic at 37 °C until OD600¼0.8–1.0. Cultures were
induced at 20 °C with 1 mM IPTG for 4 h. Cells were harvested at
Table 1
Oligonucleotides designed for site directed mutagenesis
of CDTa active site residues.
Mutation Primers
S345A 5′-CCG AAC TTT ATT GGC ACC AGC-3′
5′-GCT GGT GCC AAT AAA GTT CGG-3′
S345F 5′-CCG AAC TTT ATT TTC ACC AGC-3′
5′-GCT GGT GAA AAT AAA GTT CGG-3′
S345R 5′-CCG AAC TTT ATT CGT ACC AGC-3′
5′-GCT GGT ACG AAT AAA GTT CGG-3′
S345Y 5′-CCG AAC TTT ATT TAC ACC AGC-3′
5′-GCT GGT GTA AAT AAA GTT CGG-3′
E385Q 5′-GCT ATG CGG GCC AAT ATG AAG TG-3′
5′-CAC TTC ATA TTG GCC CGC ATA GC-3′
E387Q 5′-GGG CGA ATA TCA AGT GCT GCT G-3′
5′-CAG CAG CAC TTG ATA TTC GCC G-3′
E387R 5′-GC GAA TAT GAT GTG CTG CTG-3′
5′-CAG CAG CAC ACG ATA TTC GC-3′
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2.3. Puriﬁcation of CDTa constructs (rCTDa and mutants)
Cell pellets were re-suspended in lysis buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1 mM EDTA; 2 ml/g of pellet). Cells were
passed through a homogeniser twice at a pressure of 20kpsi at
4 °C. The cell lysate was centrifuged at 25,000 rpm for 35 min at
4 °C and the resultant supernatant was ﬁltered through both a
Minisarts GF-pre-ﬁlter (Sartorius) and 0.45 mm millex-HA ﬁlter
(Millipore). The ﬁltered supernatant was loaded onto a 5 ml
GSTrap-FF column (GE Healthcare) at 0.5 ml/min in lysis buffer.
GST-tagged CDTa constructs were eluted at 0.5 ml/min in 20 mM
reduced glutathione in lysis buffer. The GST-tag was removed
during overnight dialysis at 4 °C against 50 mM Tris-HCl pH
8.0 and 20 mM NaCl, by adding PreScission™ protease (1U per
100 μg of protein, GE Healthcare) to the puriﬁed protein. Dialyzed
protein was centrifuged at 4000g to remove any precipitated
protein and re-loaded onto the GSTrap-FF column as above. Pur-
iﬁed CDTa constructs were collected in ﬂow through, concentrated
to 5.0 mg/ml (Amicon Ultra-15, Millipore), ﬂash frozen in liquid
nitrogen and stored at 80 °C until further use.
2.4. Vero cell cytotoxicity assays
The cytotoxicity of CDTa mutants was assessed using a pre-
viously established protocol [5] with some modiﬁcations. Vero
cells have previously shown cell death in the presence of both
CDTa and CDTb′ (CDTb lacking the N-terminal signal peptide, re-
sidues 41-876, Fig. 1A), as well as TcdA and TcdB. Vero cells were
grown in Dulbecco's Modiﬁed Eagle's Medium (DMEM) containing
10% foetal calf serum (FCS) and 2 mM glutamine at 37 °C in the
presence of 5% CO2. Cells were routinely trypsinized and used to
coat 96-well plates in a volume of 200 μl (104 cells/well) of com-
plete DMEM (supplemented with 10% FCS and 2 mM glutamine)
and were incubated for 24 h to allow formation of a conﬂuent
monolayer. Prior to assays, the mediumwas carefully removed and
the cells were washed twice with Dulbecco's phosphate buffered
saline (DPBS) and the cells were incubated for 1 h in 100 μl DMEM
(supplemented with 10% FCS and 2 mM glutamine).
To test the cytotoxic effect of CDT on Vero cells, cells were in-
cubated with various components (100 μl reaction volume) for
24 h at 37 °C, 5% CO2. TcdA and TcdB were puriﬁed from C. difﬁcle
as previously described [15,16] and used as a positive control for
cell death. Cells were incubated with 50 ng/ml TcdA and 0.5 ng/mlTcdB to ensure the Vero cells were responsive to the standard
cytotoxicity assay. To establish baseline activity of CDTa-CDTb′
complex and compare it with CDTa mutants, cells were incubated
with 250 ng of each CDTa and trypsin activated CDTb′. Trypsin
activated CDTb′ was used rather than CDTb′′ (Fig. 1A) as this shows
greater cytotoxicity when combined with CDTa [5]. To exclude cell
death caused by any of the assay components, cells were incubated
with either serum free DMEM, CDTa buffer, CDTb′ buffer, 250 ng
CDTa or 250 ng trypsin activated CDTb′ (negative controls). The
cells were examined after 24 h for evidence of cytotoxic effect.
2.5. Western blot analysis
To assess whether the mutations affect CDTa binding to NAD or
transfer of ADP-ribose to actin, CDTa was incubated with biotiny-
lated NAD (biotin-NAD) and actin and reactions were analysed by
Western blotting for the presence of biotin-NAD. The NAD used
here is biotinylated at the ADP-ribose end and is accessible to an
enzyme-conjugated streptavidin antibody after ADP-ribosylation.
CDTa constructs were incubated with NAD-biotin at equal molar
ratio. Prior to adding actin to the CDTa-biotin-NAD mix in a 1:1 M
ratio, actin was incubated with latrunculin A at equal molar con-
centration to maintain actin in its monomeric form. Negative
controls included reactions without biotinylated-NAD or rCDTa to
conﬁrm that neither biotinylated-NAD nor rCDTa alone would be
detected in the blot (not shown). Reactions were incubated at
room temperature with gentle rocking for 1 h and stopped by
addition of SDS-PAGE sample loading dye (no heating). Samples
were resolved on a 10% Tris-glycine SDS-PAGE (200 V for 1 h) and
transferred to nitrocellulose membrane using standard techniques
for 1 h at 50 V. The membrane was blocked overnight in 1% bovine
serum albumin (BSA) in phosphate buffered saline pH 7.4 con-
taining 0.05% Tween-20 (PBST). The membrane was then washed
25 min in PBST, after which the membrane was incubated with
streptavidin horseradish peroxidase (strep-HRP) 1:1000 in PBST
for 1 h. The membrane was washed 65 min before adding the
developing solution: 50 mM Tris-HCl pH 7.5, 0.03% H2O2 and 0.1%
3, 3′-Diaminobenzidine (DAB). Developing solution was removed
immediately after bands appeared on the membrane to prevent
overexposure.3. Results
3.1. CDTa mutations reduce or abolish cytotoxicity
To assess the cytotoxicity of the CDTa mutants, Vero cell assays
were performed. The negative controls (Fig. 2, top row) conﬁrm
that protein buffers, rCDTa and trypsin activated CDTb′ on their
own are non-cytotoxic to Vero cells. TcdA and TcdB, which are
known to have a clear cytotoxic impact on Vero cells, were in-
cluded as positive controls to ensure that the Vero cells were re-
sponsive to the standard cytotoxicity assay. As expected TcdA or
TcdB induce cell rounding leading to cell death (Fig. 2).
rCDTa-CDTb′ (Fig. 2) also induces cell death, but not to the same
extent as TcdA and TcdB. These results are consistent with those
previously reported [1].
CDTa mutation S345A shows some cytotoxicity but the number
of rounded cells is signiﬁcantly less than in the case of rCDTa
(Fig. 2). CDTa mutants S345F, S345R, S345Y, E385Q, E387Q and
E387R show no sign of Vero cell death (cell rounding) i.e. they
abolish CDTa-CDTb’ toxicity. This suggests that these mutations
prevent ADP-ribosylation of G-actin.
Fig. 2. Vero cell cytotoxicity assay. Amount of rCDTa, mutants and CDTb′ present in cell assays was 250 ng. Reaction volume was 100 μl. TcdA and TcdB were added to a
ﬁnal concentration of 50 ng/ml and 0.5 ng/ml respectively. Size bars, 400 mm.
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In vitro cell assays suggested that impaired ADP-ribosylation may
be the major reason preventing cytotoxicity of CDTa mutants. To
determine if cytotoxicity depends only on biotin-NAD transfer to
actin or also on CDTa binding of biotin-NAD, CDTa constructs were
incubated with biotin-NAD and actin. The reactions were resolved on
SDS-PAGE (Fig. 3A) and subjected to Western blot analysis following
the presence of biotin-NAD by strep-HRP antibody (Fig. 3B). As a
control rCDTa was incubated with biotin-NAD in the absence of actin
(-actin sample) to assess binding of biotin-NAD to CDTa. As positive
control (þve control) rCDTa was incubated with biotin-NAD and
actin to conﬁrm both, biotin-NAD binding by rCDTa as well as
transfer of the ADP-ribose group to actin by rCDTa. Western blot
analysis conﬁrms that rCDTa strongly binds to biotin-NAD and
transfers biotin-NAD to actin (Fig. 3B). In comparison, in the absence
of actin, rCDTa does not bind biotin-NAD well.
CDTa mutant S345A binds and transfers biotin-NAD to the
same extent as rCDTa. These results correlate with the cytotoxicity
assays in which S345A was the only mutation that induced cell
death. S345F and S345R bind biotin-NAD but transfer to actin is
negligible (very faint band). S345R binds more biotin-NAD than
S345F but the level of biotin-NAD transfer appears similar be-
tween these mutants. Both mutants were non-cytotoxic in Vero
cell assays. Mutants S345Y, E385Q, E387Q and E387R are unable to
transfer biotin-NAD to actin. Low level of biotin-NAD binding to
E385Q, E387Q and E387R can be detected, whereas S345Y does
not bind biotin-NAD. Based on the physical difference between
serine and tyrosine, it is conceivable that the mutation caused a
signiﬁcant reduction in binding and cytotoxic efﬁciency.4. Discussion
The selected residues Glu-385 and Glu-387 of the EXE-motif of
rCDTa were mutated, as this motif is known to play a strong role in
ligand binding and catalysis [3]. They directly correspond to residues
Glu-378 and Glu-380 which were shown to play key roles in thecytotoxicity of Ia [17]. In addition Ser-345 was also selected for mu-
tagenesis studies due to its key role in binding Glu-387 and NAD.
CDT ADP-ribosylates monomeric actin, which leads to cytos-
keletal collapse and eventually to cell death. Cytotoxicity cell as-
says conﬁrmed that rCDTa-CDTb′ induces cell death and Western
blot analysis conﬁrmed that rCDTa ADP-ribosylates G-actin. In the
absence of actin, rCDTa binds lower levels of biotin-NAD as ex-
pected. SDS-PAGE reveals that the -actin sample does not correlate
with the other samples although reactions were handled in the
same manner. This is likely a result of gel loading. Consequently
the lower amount of protein present is reﬂected by the almost
undetectable biotin-NAD signal in Western analysis. Notably, in
the absence of actin, biotin-NAD is still be hydrolysed and released
from the rCDTa active site, which given its molecular weight
(244.31) is likely to run off SDS-PAGE before Western transfer. In
this case, the signal will be even lower and it would be impossible
to compare samples. To overcome inaccuracies caused by un-
controlled biotin-NAD hydrolysis reactions contained actin. In the
presence of actin, the biotin-NAD signal can be monitored either
whilst bound to CDTa constructs or actin. Western blot analysis of
CDTa mutants which had diminished or no cytotoxic effect, con-
ﬁrmed that majority of mutants had lost ADP-ribosyl transferase
activity but not the ability to bind biotin-NAD. In cytotoxicity as-
says S345A is the only mutant inducing signiﬁcant cell death, al-
beit less than rCDTa-CDTb′, there is still evidence that this muta-
tion has not inhibited the activity of CDTa but may have slightly
reduced its efﬁcacy. In Western blot analysis S345A activity mat-
ches that of rCDTa.
The inability of CDTa mutants to transfer biotin-NAD to actin
correlates with the proteins being unable to induce cell death in
vitro. Mutants E385Q, E387Q and E387R are unable to transfer
biotin-NAD but retain some ability to bind biotin-NAD.
Both the Western blot analysis and the Vero cell assay have
conﬁrmed that S345A is the only mutation that retains cytotoxi-
city. Ser-345 together with Thr-346 and Ser-347, forms the STS
motif. The S345A mutation retains the overall arrangement of NAD
in the active site and salt bridges between Arg-302, Arg-359 and
NAD are unaffected (Fig. 4A). As expected the hydrogen bond in
Fig. 3. Enzyme activity of rCDTa and CDTa mutants. 10% Tris-glycine SDS-PAGE of biotin-NAD binding and transfer assays (A) which was used for subsequent Western blot
detection of biotin-NAD via strep-HRP antibody (B). Reaction in lane -actin contained rCDTa þ biotin-NAD. All other reactions contained biotin-NAD, actin and the protein
construct stated. The Western blot was developed with DAB displaying strep-HRP bound to biotin-NAD where present on the membrane. The lanes correspond with gel
picture A. The table summarises the activity of CDTa constructs to bind and transfer NAD-biotin to actin where þþþ is maximum activity (rCDTa control) and – is lack of
activity.
A.H. Davies et al. / Biochemistry and Biophysics Reports 8 (2016) 55–61 59rCDTa between the Ser-345 hydroxyl group and one of the hy-
droxyl groups of the nicotinamide carrying ribose, as well as the
hydrogen bond with the catalytic Glu-387 are lost (Fig. 4A). Yet,
cytotoxicity assays conﬁrm that the loss of these interactions only
reduces activity of the S345A mutant. This is in agreement with
previous mutagenesis studies on corresponding residues of the
STS motif in Ia [18] and C2 [19]. By mutating a serine residue to
alanine, the –OH group is removed, whereas mutations to phe-
nylalanine, arginine or tyrosine are much more signiﬁcant in terms
of size and functional group properties. This would suggest that
the functional hydroxyl group of serine does not play an important
role in the active site. Mutation of Ser-345 to alanine only mar-
ginally reduced the cytotoxicity whereas mutants S345F, S345R
and S345Y are non- cytotoxic. Thus increase in size of the Ser-345
residue has an adverse effect on cytotoxicity which could be due to
a number of reasons. It could prevent the residue from interacting
with and stabilising Glu-387, or it could block the transfer of ADP-
ribose to actin. We identiﬁed a single mutation, S345Y, which was
able to abolish both biotin-NAD binding and transfer whereas
S345F and S345R only affect transfer. Hence, targeting CDTa abilityto transfer NAD to actin is sufﬁcient to inhibit cytotoxicity. The
enlarging effect of the residue does not seem to affect NAD binding
as demonstrated by the Western blot analysis, with the exception
of S345Y which is likely due to steric hindrance in the active site,
reducing the NAD binding capacity. Notably, phenylalanine which
is similar in structure and physical properties to tyrosine does not
block NAD binding. A model of the rCDTa active site illustrates
how 345Y blocks the space usually occupied by NAD in the wild
type structure (Fig. 4B).
The EXE-motif mutations also show interesting results. Previously
it has been suggested that the hydrolysis of NAD and ADP-ribosylation
of actin take place via an SN1 reaction, with Glu-387 playing a key role
in oxocarbenium ion formation by interaction with the 2′OH ribose
group of NAD. By creating E387Q, the hydroxyl group (-OH) of Glu-387
is substituted with an amine group (–NH2), which appears to com-
pletely abolish ADP-ribosylation of actin. This suggests that the pro-
posed SN1 reaction involving Glu-387 has some validity. In addition
E385Q also completely eliminates ADP-ribosylation of actin, which
indicates that the –OH functional group plays a crucial role in the
mechanism. The theory is that Glu-385 brings Arg-177 from actin into
Fig 4. (A) Interaction of rCDTa and CDTa S345A with NAD. Hydrogen bonding, water bridges, salt bridges, and hydrophobic interactions are shown in blue, grey, yellow
(dotted), and grey (dotted) lines respectively. Ser-345 is shown in pink and Ala-345 in green. CDTa S345A was generated using Swiss Model [20–23]. Protein ligand proﬁles
were generated using PLIP [24]. (B) Comparison of the active sites of rCDTa and CDTa S345Y. The protein structure for rCDTa has been reported previously [13], PDB accession
2WN7. rCDTa C-terminal region is shown in cyan. NAD cofactor is shown in orange. Residue Arg-177 (ribosylation site) from the modelled Actin is shown in yellow as
reference. The active site of S345Y was modelled using Swiss-Model [20–23].
A.H. Davies et al. / Biochemistry and Biophysics Reports 8 (2016) 55–6160the active site via the –OH functional group of Glu-385. Again, the
present mutagenesis study indicates this theory may also be correct.
Having already established that substitution of the functional group of
Glu-387 to –NH2 abolishes actin ADP-ribosylation, it conﬁrms the view
that increasing the size of this residue and substituting the functional
group (E387R mutation) also hinders ADP-ribosylation.
In summary, the purpose of this mutagenesis study was to
monitor the effect on cytotoxicity, and to determine whether or not
these residues are vital individually for the activity of CDTa. Combi-
nation of both the Vero cell assays and the Western blot analysis has
proven that altering three key residues has a signiﬁcant impact on
CDTa activity. This study is also supporting the proposed SN1 me-
chanism of CDTa. If the activity of CDTa can be inhibited, then ADP-
ribosylation of actin can also be prevented, which in turn will protectfrom cell rounding and cell death. The study shows that mutating
CDTa key residues affects activity but that the amino acid substitution
determines the extent by which CDTa activity is affected.Acknowledgement
This work was supported by the MRC-UK project Grant (MK/
K027123/1) to K.R.A. and C.C.S.Appendix A. Transparency document
Transparency document associated with this article can be
A.H. Davies et al. / Biochemistry and Biophysics Reports 8 (2016) 55–61 61found in the online version at http://dx.doi.org/10.1016/j.bbrep.
2016.08.011.References
[1] M.R. Popoff, E.J. Rubin, D.M. Gill, P. Boquet, Actin-speciﬁc ADP-ribosyl-
transferase produced by a Clostridium difﬁcile strain, Infect. Immun. 56 (1988)
2299–2306.
[2] H. Barth, Uptake of binary actin ADP-ribosylating toxins, Rev. Physiol. Biochem.
Pharmacol. 152 (2004) 165–182.
[3] A.H. Davies, A.K. Roberts, C.C. Shone, K.R. Acharya, Super toxins from a super
bug: structure and function of Clostridium difﬁcile toxins, Biochem. J. 436
(2011) 517–526.
[4] S. Perelle, M. Gibert, P. Bourlioux, G. Corthier, M.R. Popoff, Production of a
complete binary toxin (actin-speciﬁc ADP- ribosyltransferase) by Clostridium
difﬁcile CD196, Infect. Immun. 65 (1997) 1402–1407.
[5] A. Sundriyal, A.K. Roberts, R. Ling, J. McGlashan, C.C. Shone, K.R. Acharya,
Expression, puriﬁcation and cell cytotoxicity of actin-modifying binary toxin
from Clostridium difﬁcile, Protein Expr. Purif. 74 (2010) 42–48.
[6] D.N. Gerding, S. Johnson, M. Rupnik, K. Aktories, Clostridium difﬁcile binary
toxin CDT: mechanism, epidemiology, and potential clinical importance, Gut
Microbes 5 (2013) 15–27.
[7] C. Schwan, B. Stecher, T. Tzivelekidis, M. Van Ham, M. Rohde, W.D. Hardt, et al.,
Clostridium difﬁcile toxin CDT induces formation of microtubule-based pro-
trusions and increases adherence of bacteria, PLoS Pathog. 5 (2009) e1000626.
[8] H. Barth, K. Aktories, M.R. Popoff, B.G. Stiles, Binary bacterial toxins: bio-
chemistry, biology, and applications of common Clostridium and Bacillus pro-
teins, Microbiol. Mol. Biol. Rev. 68 (2004) 373–402.
[9] I. Gülke, G. Pfeifer, J. Liese, M. Fritz, F. Hofmann, K. Aktories, et al., Char-
acterization of the enzymatic component of the ADP-ribosyltransferase toxin
CDTa from Clostridium difﬁcile, Infect. Immun. 69 (2001) 6004–6011.
[10] H. Tsuge, M. Nagahama, M. Oda, S. Iwamoto, H. Utsunomiya, V.E. Marquez,
et al., Structural basis of actin recognition and arginine ADP-ribosylation by
Clostridium perfringens iota-toxin, Proc. Natl. Acad. Sci. USA 105 (2008)
7399–7404.
[11] J. Vandekerckhove, B. Schering, M. Bärmann, K. Aktories, Clostridium perfrin-
gens iota toxin ADP-ribosylates skeletal muscle actin in Arg-177, FEBS Lett. 225(1987) 48–52.
[12] S. Mauss, C. Chaponnier, I. Just, K. Aktories, G. Gabbiani, ADP-ribosylation of
actin Isoforms by Clostridium botulinum C2 Toxin and Clostridium perfringens
Iota Toxin, Eur. J. Biochem. 194 (1990) 237–241.
[13] A. Sundriyal, A.K. Roberts, C.C. Shone, K.R. Acharya, Structural basis for sub-
strate recognition in the enzymatic component of ADP-ribosyltransferase
toxin CDTa from Clostridium difﬁcile, J. Biol. Chem. 284 (2009) 28713–28719.
[14] K.P. Holbourn, C.C. Shone, K.R. Acharya, A family of killer toxins: exploring the
mechanism of ADP-ribosylating toxins, FEBS J. 273 (2006) 4579–4593.
[15] A.K. Roberts, C.C. Shone, Modiﬁcation of surface histidine residues abolishes
the cytotoxic activity of Clostridium difﬁcile toxin A, Toxicon 39 (2001)
325–333.
[16] A. Roberts, J. Mcglashan, A.A. Ibrahim, R. Ling, H. Denton, S. Green, et al.,
Development and evaluation of an ovine antibody-based platform for treat-
ment of Clostridium difﬁcile infection, Infect. Immun. 80 (2012) 875–882.
[17] S. Perelle, M. Domenighini, M.R. Popoff, Evidence that Arg-295, Glu-378, and
Glu-380 are active-site residues of the ADP-ribosyltransferase activity of iota
toxin, FEBS Lett. 395 (1996) 191–194.
[18] M. Nagahama, Y. Sakaguchi, K. Kobayashi, S. Ochi, J. Sakurai, Characterization
of the enzymatic component of Clostridium perfringens iota-toxin, J. Bacteriol.
182 (2000) 2096–2103.
[19] H. Barth, J.C. Preiss, F. Hofmann, K. Aktories, Characterization of the catalytic
site of the botulinum C2 toxin by site-directed mutagenesis characterization of
the catalytic site of the ADP-ribosyltransferase Clostridium botulinum C2 toxin
by site-directed Mutagenesis, J. Biol. Chem. 273 (1998) 29506–29511.
[20] K. Arnold, L. Bordoli, J. Kopp, T. Schwede, The SWISS-MODEL workspace: a
web-based environment for protein structure homology modelling, Bioinfor-
matics 22 (2006) 195–201.
[21] M. Biasini, S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, et al.,
SWISS-MODEL: modelling protein tertiary and quaternary structure using
evolutionary information, Nucleic Acids Res. 42 (2014) 252–258.
[22] N. Guex, M.C. Peitsch, T. Schwede, Automated comparative protein structure
modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective,
Electrophoresis 30 (2009) 162–173.
[23] F. Kiefer, K. Arnold, M. Künzli, L. Bordoli, T. Schwede, The SWISS-MODEL re-
pository and associated resources, Nucleic Acids Res. 37 (2009) 387–392.
[24] S. Salentin, S. Schreiber, V.J. Haupt, M.F. Adasme, M. Schroeder, PLIP: fully
automated protein-ligand interaction proﬁler, Nucleic Acids Res. 43 (2015)
W443–W447.
